How to buy Inovio Pharmaceuticals stock | $11.49

Inovio Pharmaceuticals, Inc is a biotechnology business based in the US. Inovio Pharmaceuticals shares (INO) are listed on the NASDAQ and all prices are listed in US Dollars. Inovio Pharmaceuticals employs 190 staff and has a trailing 12-month revenue of around USD$2.1 million.

How to buy shares in Inovio Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Inovio Pharmaceuticals. Find the stock by name or ticker symbol: INO. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Inovio Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$11.49, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Inovio Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Inovio Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced investors

Webull

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.

What's in this guide?

1. INO shares summary
2. Compare share dealing platforms
3. Is INO stock a buy or sell?
4. Stock performance over time
5. Can I short INO shares?
6. Inovio Pharmaceuticals's financials
7. How volatile are INO shares?
8. Does Inovio Pharmaceuticals pay a dividend?
9. Have INO shares ever split?
10. Other common questions

Inovio Pharmaceuticals share price

Use our graph to track the performance of INO stocks over time.

Inovio Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-03-02.

Latest market close	USD$11.49
52-week range	USD$5.13 - USD$33.79
50-day moving average	USD$12.103
200-day moving average	USD$11.755
Wall St. target price	USD$16.14
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.215

Buy Inovio Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Webull		$0	Stocks, Options, ETFs	$0	0%	Get two free stock valued between $2.50 and $250 Open an account	Margin financing rates start at 3.99%. No monthly subscription fees for margin.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Inovio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Inovio Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inovio Pharmaceuticals price performance over time

Historical closes compared with the close of $11.49 from 2021-02-25

1 week (2021-02-22)	N/A
1 month (2021-02-01)	N/A
3 months (2020-12-01)	N/A
6 months (2020-09-01)	N/A

1 year (2020-03-01)	N/A
2 years (2019-03-01)	N/A
3 years (2018-03-01)	N/A
5 years (2016-03-01)	N/A

Shorting Inovio Pharmaceuticals shares

There are currently 43.1 million Inovio Pharmaceuticals shares held short by investors – that's known as Inovio Pharmaceuticals's "short interest". This figure is 0.5% down from 43.3 million last month.

There are a few different ways that this level of interest in shorting Inovio Pharmaceuticals shares can be evaluated.

Inovio Pharmaceuticals's "short interest ratio" (SIR)

Inovio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Inovio Pharmaceuticals shares currently shorted divided by the average quantity of Inovio Pharmaceuticals shares traded daily (recently around 22.6 million). Inovio Pharmaceuticals's SIR currently stands at 1.91. In other words for every 100,000 Inovio Pharmaceuticals shares traded daily on the market, roughly 1910 shares are currently held short.

However Inovio Pharmaceuticals's short interest can also be evaluated against the total number of Inovio Pharmaceuticals shares, or, against the total number of tradable Inovio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inovio Pharmaceuticals's short interest could be expressed as 0.21% of the outstanding shares (for every 100,000 Inovio Pharmaceuticals shares in existence, roughly 210 shares are currently held short) or 0.2142% of the tradable shares (for every 100,000 tradable Inovio Pharmaceuticals shares, roughly 214 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inovio Pharmaceuticals.

Find out more about how you can short Inovio Pharmaceuticals stock.

Have Inovio Pharmaceuticals's shares ever split?

Inovio Pharmaceuticals's shares were split on a 1:4 basis on 6 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Inovio Pharmaceuticals shares which in turn could have impacted Inovio Pharmaceuticals's share price.

Inovio Pharmaceuticals share price volatility

Over the last 12 months, Inovio Pharmaceuticals's shares have ranged in value from as little as $5.13 up to $33.79. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 0.9963. This would suggest that Inovio Pharmaceuticals's shares are less volatile than average (for this exchange).

Inovio Pharmaceuticals overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Frequently asked questions

• What percentage of Inovio Pharmaceuticals is owned by insiders or institutions?

  Currently 2.166% of Inovio Pharmaceuticals shares are held by insiders and 36.486% by institutions.

• How many people work for Inovio Pharmaceuticals?

  Latest data suggests 190 work at Inovio Pharmaceuticals.

• When does the fiscal year end for Inovio Pharmaceuticals?

  Inovio Pharmaceuticals's fiscal year ends in December.

• Where is Inovio Pharmaceuticals based?

  Inovio Pharmaceuticals's address is: 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

• What is Inovio Pharmaceuticals's ISIN number?

  Inovio Pharmaceuticals's international securities identification number is: US45773H2013

• What is Inovio Pharmaceuticals's CUSIP number?

  Inovio Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 371916107